Literature DB >> 25076066

Prevalence, investigational pathways and diagnostic outcomes in differing irritable bowel syndrome subtypes.

Simone Lin1, Peter D Mooney, Matthew Kurien, Imran Aziz, John S Leeds, David S Sanders.   

Abstract

BACKGROUND: There has been increasing interest in subclassifying irritable bowel syndrome (IBS) to make a positive diagnosis. AIM: The aim of this study was to assess the population prevalence of differing subtypes, investigational pathways and diagnostic outcomes.
MATERIALS AND METHODS: Data were prospectively collected from three groups between 2005 and 2012. Group 1 [n=1002, 55% female, mean age 39 years (range 16-93 years)] comprised healthy volunteers who were interviewed using the Rome III diagnostic questionnaire. In secondary care, group 2 [n=64, 80% female, mean age 44 years (range 23-79 years)] comprised patients with constipation-predominant IBS (IBS-C) and group 3 [n=333, 66% female, mean age 51 years (range 23-92 years)] comprised patients with diarrhoea-predominant IBS (IBS-D). In groups 2 and 3, demographic data and diagnostic yield of investigations were evaluated as per normal clinical practice.
RESULTS: IBS prevalence in group 1 was 6% (60/1002). IBS-C patients were significantly older than those with IBS-D (mean age 45 vs. 30 years, P=0.027). In groups 2 and 3, patients with IBS-C underwent a total of 56 additional investigations (mean 0.88 per patient), which was significantly lower than the number of investigations undertaken in the IBS-D group of 734 (mean 2.2 per patient, P<0.001). Further investigations in group 3 (IBS-D) identified an alternative diagnosis in 22%, whereas in group 2 (IBS-C) this was 0% (P<0.0001).
CONCLUSION: This is the first study to evaluate the population prevalence of different IBS subtypes within a UK population. Although further investigations in IBS-D patients have led to alternative diagnoses, none were identified in the IBS-C population. The merits of investigating IBS-C patients should be questioned.

Entities:  

Mesh:

Year:  2014        PMID: 25076066     DOI: 10.1097/MEG.0000000000000171

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Multicenter observational study on functional bowel disorders diagnosed using Rome III diagnostic criteria in Japan.

Authors:  Masayoshi Ono; Mototsugu Kato; Shuichi Miyamoto; Momoko Tsuda; Takeshi Mizushima; Shouko Ono; Manabu Nakagawa; Katsuhiro Mabe; Soichi Nakagawa; Shuichi Muto; Yuichi Shimizu; Mineo Kudo; Shinichi Katsuki; Takashi Meguro; Naoya Sakamoto
Journal:  J Gastroenterol       Date:  2018-01-05       Impact factor: 7.527

2.  Burden of irritable bowel syndrome in an increasingly cost-aware National Health Service.

Authors:  Anet Soubieres; Patrick Wilson; Andrew Poullis; Julia Wilkins; Mark Rance
Journal:  Frontline Gastroenterol       Date:  2015-02-24

3.  Psychiatric Co-morbidity in Patients With Irritable Bowel Syndrome at a Tertiary Care Center in Northern India.

Authors:  Yuman Kawoos; Zaid A Wani; Showkat A Kadla; Irfan A Shah; Arshad Hussain; M Maqbool Dar; Mushtaq A Margoob; Kouser Sideeq
Journal:  J Neurogastroenterol Motil       Date:  2017-10-30       Impact factor: 4.924

Review 4.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

5.  Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World.

Authors:  Tadayuki Oshima; Hiroto Miwa
Journal:  J Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 4.924

6.  Elevated Circulating hsa-miR-106b, hsa-miR-26a, and hsa-miR-29b in Type 2 Diabetes Mellitus with Diarrhea-Predominant Irritable Bowel Syndrome.

Authors:  Wenhua Tao; Xiaoyun Dong; Guimei Kong; Penghua Fang; Xiaoli Huang; Ping Bo
Journal:  Gastroenterol Res Pract       Date:  2016-08-22       Impact factor: 2.260

7.  Ameliorative effects of atractylodin on intestinal inflammation and co-occurring dysmotility in both constipation and diarrhea prominent rats.

Authors:  Changchun Yu; Yongjian Xiong; Dapeng Chen; Yanli Li; Bin Xu; Yuan Lin; Zeyao Tang; Chunling Jiang; Li Wang
Journal:  Korean J Physiol Pharmacol       Date:  2016-12-21       Impact factor: 2.016

8.  Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials.

Authors:  Anthony J Lembo; Paul S Covington; Leonard S Dove; David A Andrae
Journal:  Neurogastroenterol Motil       Date:  2020-01-27       Impact factor: 3.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.